Home of Hepatology7 rue Daubin1203 GenevaSwitzerland+41 22 807 03 60easloffice@easloffice.eu© 2025 EASL. All rights reserved.Website by Soto.Privacy Policy | Cookie Policy | Terms & Conditions | Cyber Security Explore offerUnlock the full potential of being part of the EASLcommunity. As a member, you’ll gain access toexclusive resources, reduced event fees, top-tierjournals, and professional development opportunitiesdesigned to support your career in hepatologyBecome a memberNurses & Allied Health ProfessionalsLink titleYoung InvestigatorsLink titleBasic ScienceLink titleTitle here Lorem ipsum At the heart of EASL is a diverse and dynamic international community of professionals dedicated to advancing hepatology.Discover how you can get involved and make an impact.Whether you're a member, a Young Investigator, a nurse or allied health professional, or focused on basic science, there's a place for you here. Explore the different pathways to connect, grow and contribute, from membership benefits to tailored programmes and scientific networksLorem ipsum dolor sit ipsum CommunitySign In / Sign UpResourcesWhat We DoAbout Us Partnerships

Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy

On the eve of the rare disease day, our guests will discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk will address the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.

Faculty: Aleksander Krag (Moderator), Aftab Ala (Faculty), Pavel Strnad (Faculty), Alice Turner (Faculty)

Related episodes:

This episode is scheduled in honour of the Rare Disease Day (29 February).

Scroll to Top

Search EASL